49.86

4.03% +1.93

After Hours: 50.16 0.30 +0.60%

Apellis Pharmaceuticals Inc (APLS)

Overview News Price History Option Chain Why APLS Down? Discussions Forecast

Apellis Pharmaceuticals Inc stock is currently priced at $49.86, with a 24-hour trading volume of 1.21M. It has seen a +4.03% increased in the last 24 hours and a -15.49% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $48.09 pivot point. If it approaches the $50.38 resistance level, significant changes may occur.

Previous Close:

$47.93

Open:

$50

24h Volume:

1.21M

Market Cap:

$6.01B

Revenue:

$396.59M

Net Income/Loss:

$-528.63M

P/E Ratio:

-9.4971

EPS:

-5.25

Net Cash Flow:

$-595.51M

1W Performance:

+4.90%

1M Performance:

-15.49%

6M Performance:

+2.91%

1Y Performance:

-41.12%

1D Range:

$48.85

$50.98

52W Range:

$19.83

$94.75

Apellis Pharmaceuticals Inc Stock (APLS) Company Profile

Name

Apellis Pharmaceuticals Inc

Sector

Healthcare (1199)

Industry

Biotechnology (688)

Phone

502-241-4114

Address

6400 Westwind Way, Suite A, Crestwood, KY

Employee

Twitter

@ApellisPharma

Next Earnings Date

2024-05-07

Latest SEC Filings

APLS's Discussions on Twitter

Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-05-24	Upgrade	Jefferies	Hold → Buy
Dec-14-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Nov-09-23	Initiated	Goldman	Buy
Nov-02-23	Initiated	Mizuho	Neutral
Oct-06-23	Upgrade	JP Morgan	Neutral → Overweight
Sep-15-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Aug-29-23	Reiterated	Citigroup	Buy
Aug-03-23	Downgrade	JP Morgan	Overweight → Neutral
Aug-01-23	Downgrade	BofA Securities	Buy → Neutral
Jan-03-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Nov-10-22	Downgrade	Jefferies	Buy → Hold
Jul-19-22	Initiated	H.C. Wainwright	Buy
Jun-17-22	Resumed	Stifel	Buy
Apr-14-22	Downgrade	ROTH Capital	Neutral → Sell
Dec-08-21	Initiated	Wells Fargo	Overweight
Nov-29-21	Downgrade	ROTH Capital	Buy → Neutral
Sep-10-21	Reiterated	BMO Capital Markets	Outperform
Sep-10-21	Reiterated	Credit Suisse	Neutral
Sep-10-21	Reiterated	Needham	Buy
Sep-10-21	Reiterated	Oppenheimer	Outperform
Sep-10-21	Downgrade	Wedbush	Outperform → Neutral
Aug-19-21	Initiated	Jefferies	Buy
Aug-19-21	Upgrade	Wedbush	Neutral → Outperform
May-21-21	Initiated	UBS	Buy
Apr-16-21	Initiated	Goldman	Buy
Nov-19-20	Initiated	Needham	Buy
Sep-01-20	Initiated	Stifel	Buy
Jul-20-20	Initiated	ROTH Capital	Buy
Jun-17-20	Initiated	BTIG Research	Neutral
Apr-01-20	Initiated	Raymond James	Strong Buy
Mar-31-20	Initiated	BMO Capital Markets	Outperform
Mar-11-20	Upgrade	Wedbush	Underperform → Neutral
Jan-07-20	Initiated	SVB Leerink	Mkt Perform
Dec-19-19	Initiated	BofA/Merrill	Buy
Nov-22-19	Initiated	Wedbush	Underperform
Nov-05-19	Initiated	Credit Suisse	Neutral
Aug-01-19	Reiterated	Cantor Fitzgerald	Overweight
Jul-12-19	Upgrade	JP Morgan	Neutral → Overweight
Mar-29-19	Initiated	Robert W. Baird	Outperform
Jan-23-19	Downgrade	JP Morgan	Overweight → Neutral
Jul-30-18	Upgrade	B. Riley FBR	Neutral → Buy
May-24-18	Initiated	Cantor Fitzgerald	Overweight
Apr-12-18	Downgrade	B. Riley FBR, Inc.	Buy → Neutral
Feb-08-18	Initiated	B. Riley FBR, Inc.	Buy

View All

Apellis Pharmaceuticals Inc Stock (APLS) Latest News

Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)

GlobeNewswire Inc.

Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results

GlobeNewswire Inc.

Expert Ratings For Apellis Pharmaceuticals

Benzinga

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire Inc.

Apellis Pharmaceuticals (APLS) Down 8.7% Since Last Earnings Report: Can It Rebound?

Zacks Investment Research

Apellis Pharmaceuticals Inc Stock (APLS) Financials Data

Apellis Pharmaceuticals Inc (APLS) Revenue 2024

APLS reported a revenue (TTM) of $396.59 million for the quarter ending December 31, 2023, a +425.83% rise year-over-year.

Apellis Pharmaceuticals Inc (APLS) Net Income 2024

APLS net income (TTM) was -$528.63 million for the quarter ending December 31, 2023, a +18.94% increase year-over-year.

Apellis Pharmaceuticals Inc (APLS) Cash Flow 2024

APLS recorded a free cash flow (TTM) of -$595.51 million for the quarter ending December 31, 2023, a -15.57% decrease year-over-year.

Apellis Pharmaceuticals Inc (APLS) Earnings per Share 2024

APLS earnings per share (TTM) was -$4.48 for the quarter ending December 31, 2023, a +26.92% growth year-over-year.

Apellis Pharmaceuticals Inc Stock (APLS) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Dunlop A. Sinclair	Director	Apr 12 '24	Option Exercise	13.19	1,500	19,785	133,518
Deschatelets Pascal	Chief Scientific Officer	Apr 08 '24	Option Exercise	3.76	69,107	259,842	1,185,090
Deschatelets Pascal	Chief Scientific Officer	Apr 08 '24	Sale	54.17	69,107	3,743,605	1,115,983
Sullivan Timothy Eugene	Chief Financial Officer	Apr 01 '24	Option Exercise	10.03	4,000	40,120	97,338
Sullivan Timothy Eugene	Chief Financial Officer	Apr 01 '24	Sale	58.66	4,000	234,640	93,338
Dunlop A. Sinclair	Director	Mar 19 '24	Sale	57.18	18,681	1,068,161	173,998
DeLong Mark Jeffrey	Chief Business & Strat Officer	Mar 18 '24	Sale	56.90	9,913	564,050	54,693
Chopas James George	VP/Chief Accounting Officer	Mar 15 '24	Sale	56.46	184	10,389	38,883
Nicholson Nur	Chief Technical Officer	Mar 13 '24	Sale	57.56	11,220	645,838	56,287
Deschatelets Pascal	Chief Scientific Officer	Mar 08 '24	Option Exercise	3.67	69,107	253,623	1,185,090

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology. The company develops APL-2 for intravitreal injection that is an injection into the eye, as well as subcutaneous injection, which is an injection into the tissue under the skin. It also develops APL-9 for intravenous administration in systemic indications, which is in single ascending dose Phase I clinical trial. The company has a development agreement with Enable Injections, Inc. to develop wearable devices for subcutaneous delivery of high-volume therapeutics. Apellis Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Crestwood, Kentucky.